Progress of Research and Application in Hepatitis C Virus Animal Model

doi:10.3969/j.issn.1674-5817.2013.05.018

Abstract

Abstract: Hepatitis C virus (HCV) is one of the major causes of the chronic hepatitis, cirrhosis and hepatocellular carcinoma, affecting more than 170 million people worldwide. The most sensitive species to HCV are restricted to humans and primates. The study on HCV infection mechanism, variation, replication, translation and interaction between the virus and human body were limited for lack of stable sensitive animal models. This review introduces the progress of research and application in HCV animal model.

Key words: Hepatitis C virus, Animal model

CLC Number:

Q95-33

YU Yao-cheng, WANG Ai-qin, YIN Wen, HU Xing-bin. Progress of Research and Application in Hepatitis C Virus Animal Model[J]. Laboratory Animal and Comparative Medicine, 2013, 33(5): 411-414.

References

[1] Vanwolleghem T, Libbrecht L, Hansen BE, et al.Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice[J]. J Hepatol, 2010, 53(3):468-476.
[2] Houghton M.The long and winding road leading to the identification of the hepatitis C virus[J]. J Hepatol, 2009, 51(5):939-948.
[3] Muchmore E, Popper H, Peterson DA, et al.Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee[J]. J Med Primatol, 1988, 17(5):235-246.
[4] Olsen DB, Davies ME, Handt L, et al.Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct acting antiviral agents[J]. Antimicrob Agents Chemother, 2011, 55(2):937-939.
[5] Tomoguri T, Katayama K, Tanaka J, et al.Interferon alone or combined with ribavirin for acute prolonged infection with hepatitis C virus in chimpanzees[J]. Intervirology, 2011, 54(4):229-232.
[6] Thimme R, Bukh J, Spangenberg HC, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J]. Proc Natl Acad Sci USA, 2002, 99(24):15661-15668.
[7] Shoukry NH, Sidney J, Sette A, et al.Conserved hierarchy of helper T cell response in a chimpanzee during primary and secondary hepatitis C virus infections[J]. J Immunol, 2004, 172(1):483-492.
[8] Barth H, Rybczynska J, Patient R, et al.Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees[J]. Hepatol, 2011, 54(4):1135-1148.
[9] Kolykhalov AA, Agapov EV, Blight KJ.et al.Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA[J]. Sci,1997, 277:570-574.
[10] Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J]. Sci , 2003, 302:659-662.
[11] Houghton M.Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses[J]. Immunol. 2011, 239:99-108.
[12] Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al.Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection[J]. Sci, 2010, 327:198-201.
[13] Mercer DF, Schiller DE, Elliott JF, et al.Hepatitis C virus replication in mice with chimeric human livers[J]. Nat Med, 2001, 7(8):927-933.
[14] Meuleman P, Libbrecht L, De Vos R, et al.Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera[J]. Hepatol, 2005, 41(4):847-856.
[15] Steenbergen RH, Joyce MA, Lund G, et al.Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success[J]. Am J Physiol Gastrointest Liver Physiol, 2010, 299(4):G844-G854.
[16] Kamiya N, Iwao E, Hiraga N, et al.Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor[J]. J Gen Virol, 2010, 91(Pt 7):1668-1677.
[17] Ouyang EC, Wu CH, Walton C, et al.Transplantation of human hepatocytes into tolerized genetically immunocompetent rats[J]. World J Gastroenterol, 2001, 7(3): 324-330.
[18] Wu GY, Konishi M, Walton CM, et al.A novel immunocompetent rat model of HCV infection and hepatitis[J]. Gastroenterol, 2005, 128(5): 1416-1423.
[19] Barth H, Robinet E, Liang TJ, et al.Mouse models for the study of HCV infection and virus-host interactions[J]. J Hepatol, 2008, 49(1):134-142.
[20] Washburn ML, Bility MT, Zhang L, et al.A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease[J].Gastroenterol, 2011, 140(4):1334-1344.
[21] Bukh J, Meuleman P, Tellier R, et al.Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models[J]. J Infect Dis, 2010, 201:1381-1389.
[22] Naas T, Ghorbani M, Alvarez-Maya I, et al.Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2[J]. J Gen Virol, 2005, 86(Pt 8): 2185-2196.
[23] Koike K, Moriya K, Matsuura Y.Animal models for hepatitis C and related liver disease[J].Hepatol Res, 2010, 40(1):69-82.
[24] 闫虎, 路遥, 杜娟, 等. 丙型肝炎病毒NS3/4A丝氨酸蛋白酶瞬时表达小鼠模型的建立[J].生物技术通讯, 2011, 22(4):527-531.
[25] Satoh K, Takahashi H, Matsuda C, et al.Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice[J]. J Med Virol, 2010, 82(9):1545-1553.
[26] Xie ZC, Riezu-Boj JI, Lasarte JJ, et al.Transmission of hepatitis C virus infection to tree shrews[J]. Virol, 1998, 244(2):513-520.
[27] Amako Y, Tsukiyama-Kohara K, Katsume A, et al.Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri[J]. J Virol, 2010, 84(1):303-311.
[28] Tong Y, Zhu Y, Xia X, et al.Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection[J]. J Virol, 2011, 85(6):2793-2802.
[29] Xu X, Chen H, Cao X, et al.Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma[J]. J Gen Virol, 2007, 88(Pt9): 2504-2512.